185 related articles for article (PubMed ID: 11858563)
1. The whole story: treatment outcomes with Symbicort.
Zetterström ; Buhl R; Mellem H; Andersson F
Respir Med; 2002 Feb; 96 Suppl A():S29-35. PubMed ID: 11858563
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy.
Price D; Wirén A; Kuna P
Allergy; 2007 Oct; 62(10):1189-98. PubMed ID: 17845590
[TBL] [Abstract][Full Text] [Related]
3. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study.
FitzGerald JM; Sears MR; Boulet LP; Becker AB; McIvor AR; Ernst P; Smiljanic-Georgijev NM; Lee JS;
Can Respir J; 2003; 10(8):427-34. PubMed ID: 14679407
[TBL] [Abstract][Full Text] [Related]
4. Symbicort: controlling asthma in adults.
Lalloo U
Respir Med; 2002 Feb; 96 Suppl A():S16-22. PubMed ID: 11858561
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study.
Price D; Haughney J; Lloyd A; Hutchinson J; Plumb J
Curr Med Res Opin; 2004 Oct; 20(10):1671-9. PubMed ID: 15462701
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
[TBL] [Abstract][Full Text] [Related]
7. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma.
Brüggenjürgen B; Selim D; Kardos P; Richter K; Vogelmeier C; Roll S; Meyer-Sabellek W; Buhl R; Willich SN
Pharmacoeconomics; 2005; 23(7):723-31. PubMed ID: 15987228
[TBL] [Abstract][Full Text] [Related]
8. Symbicort: controlling asthma in children.
Tal A
Respir Med; 2002 Feb; 96 Suppl A():S23-8. PubMed ID: 11858562
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.
Wickstrøm J; Dam N; Malmberg I; Hansen BB; Lange P
Clin Respir J; 2009 Jul; 3(3):169-80. PubMed ID: 20298400
[TBL] [Abstract][Full Text] [Related]
10. Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months.
Rosenhall L; Borg S; Andersson F; Ericsson K
Int J Clin Pract; 2003 Oct; 57(8):662-7. PubMed ID: 14627174
[TBL] [Abstract][Full Text] [Related]
11. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study.
Lundborg M; Wille S; Bjermer L; Tilling B; Lundgren M; Telg G; Ekström T; Selroos O
Curr Med Res Opin; 2006 May; 22(5):809-21. PubMed ID: 16709303
[TBL] [Abstract][Full Text] [Related]
12. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.
Miller E; FitzGerald JM
Can J Clin Pharmacol; 2008; 15(2):e165-76. PubMed ID: 18515918
[TBL] [Abstract][Full Text] [Related]
13. Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study.
Ind PW; Haughney J; Price D; Rosen JP; Kennelly J
Respir Med; 2004 May; 98(5):464-75. PubMed ID: 15139576
[TBL] [Abstract][Full Text] [Related]
14. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management.
Louis R; Joos G; Michils A; Vandenhoven G
Int J Clin Pract; 2009 Oct; 63(10):1479-88. PubMed ID: 19769705
[TBL] [Abstract][Full Text] [Related]
15. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing.
Canonica GW; Castellani P; Cazzola M; Fabbri LM; Fogliani V; Mangrella M; Moretti A; Paggiaro P; Sanguinetti CM; Vignola AM;
Pulm Pharmacol Ther; 2004; 17(4):239-47. PubMed ID: 15219269
[TBL] [Abstract][Full Text] [Related]
16. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.
Miller E; Sears MR; McIvor A; Liovas A
Can Respir J; 2007; 14(5):269-75. PubMed ID: 17703241
[TBL] [Abstract][Full Text] [Related]
17. Single-inhaler combination therapy for maintenance and relief of asthma: a new strategy in disease management.
Peters M
Drugs; 2009; 69(2):137-50. PubMed ID: 19228072
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
Mittmann N; Hernandez P; Mellström C; Brannman L; Welte T
Pharmacoeconomics; 2011 May; 29(5):403-14. PubMed ID: 21504240
[TBL] [Abstract][Full Text] [Related]
19. Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma.
McCormack PL; Lyseng-Williamson KA
Drugs; 2007; 67(16):2407-31. PubMed ID: 17983258
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
Löfdahl CG; Ericsson A; Svensson K; Andreasson E
Pharmacoeconomics; 2005; 23(4):365-75. PubMed ID: 15853436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
